CompletedNot Applicable

MCO Membrane Efficiency in Septic Shock Patients

Italy20 participantsStarted 2017-12-31

Plain-language summary

This is a monocentre randomized pilot study. All patients received two consecutive RRT: CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover randomized to sequence (A+B or B+A) for 48 h total without washout.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years; * septic shock according to ACCP/SCCM criteria * AKI KDIGO stage 3 * clinical decision to begin citrate based-RRT for at least 48 hours * Hb \>= 9 g/dL * Obtain the informed consent Exclusion Criteria: * Pre-existing chronic renal insufficiency * Weight \> 125 kg Life expectancy \<24 hr * Declared do Not Resuscitate or Comfort Measures * Platelets \< 20 \[10\^3/ul\] or active bleeding * Pregnancy * Contraindication to citrate